Delivery Order SPE2DB24D3013-SPE2DB24FFGKD

Award Date 7/24/24
Potential Completion Date 7/25/24
Potential Value $2.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
The U.S. Defense Logistics Agency (DLA) awarded a $3,800.16 firm fixed-price delivery order contract to Amerisourcebergen Drug Corp for the supply of 4565253592 ELIQUIS 2.5 MG TABLET 60S. This order is part of a larger Indefinite Delivery Contract (IDC) between DLA Troop Support Medical and Amerisourcebergen, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract...
The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $1,900.08 to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide ELIQUIS 2.5 MG TABLET 60S. This delivery order is part of an Indefinite Delivery Contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds with DLA to deliver pharmaceutical products and medical supplies in support of military treatment programs and facilities...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract worth $3,800.16 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, for the supply of 4564016271 ELIQUIS 2.5 MG TABLET 60S. This delivery order is a part of a larger indefinite delivery contract (IDC) valued up to $999,999,999.00 awarded by DLA to AmerisourceBergen Drug Corp, which serves as the primary vehicle for the company to provide pharmaceutical products and medical...
The U.S. Defense Logistics Agency (DLA) awarded a $1,965.60 Firm Fixed Price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of ELIQUIS 2.5 MG TABLET 60S. This contract is not set aside and has an ultimate completion date of June 12, 2025. AmerisourceBergen Drug Corp holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle with a...
The U.S. Department of Defense's Defense Logistics Agency (DLA) Troop Support Medical has awarded a $1,900.08 firm-fixed-price delivery order to Amerisourcebergen Drug Corp's Corporate Office Division for the supply of 4565177698 ELIQUIS 2.5 MG TABLET 60S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the provision of a comprehensive range of pharmaceutical and medical supplies to...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract valued at $1,900.08 to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical company Amerisourcebergen Corporation. This order is for the supply of ELIQUIS 2.5 mg tablets and is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the primary...
The U.S. Defense Logistics Agency (DLA) awarded a $3,851.90 firm fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4567732654 ELIQUIS 5 MG TABLET 60S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies...
The U.S. Defense Logistics Agency (DLA) awarded a $3,074.77 delivery order contract to Amerisourcebergen Drug Corp for the supply of ELIQUIS 5 MG TABLET 60S. The contract has a firm fixed price and an ultimate completion date of September 18, 2024. Amerisourcebergen, a major pharmaceutical distributor, has an Indefinite Delivery Contract (IDC) valued at up to $999,999,999 with DLA Troop Support Medical for delivering a wide range of medical commodities to support military treatment programs....
The Defense Logistics Agency (DLA) awarded a firm-fixed price delivery order contract to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical distributor. The $18,759.84 contract is for the supply of ELIQUIS 5 MG TABLET 60S, with a performance period through August 13, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for delivering a comprehensive range of...
The U.S. Defense Logistics Agency (DLA) awarded a $9,388.10 firm fixed price delivery order contract to Amerisourcebergen Drug Corp Corporate Office Division, a major pharmaceutical distributor, to provide ELIQUIS 5 MG TABLET 60S. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025 between DLA Troop Support Medical and Amerisourcebergen, which enables the agency to efficiently procure a comprehensive range of medical...
  • SPE2DB24D3013
    Indefinite Delivery Contract
  • SPE2DB24D3013-SPE2DB24FFGKD
    Delivery Order

The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to AmerisourceBergen Drug Corp's Corporate Office division, a for-profit pharmaceutical distributor. The $2,850.12 contract is for the supply of 4565243575 ELIQUIS 2.5 MG TABLET 60S. This order is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, for delivering a range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and has a completion date of July 25, 2024.

Generated 10/23/24, 9:12 AM